HRP20141172T1 - Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 - Google Patents
Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 Download PDFInfo
- Publication number
- HRP20141172T1 HRP20141172T1 HRP20141172AT HRP20141172T HRP20141172T1 HR P20141172 T1 HRP20141172 T1 HR P20141172T1 HR P20141172A T HRP20141172A T HR P20141172AT HR P20141172 T HRP20141172 T HR P20141172T HR P20141172 T1 HRP20141172 T1 HR P20141172T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compounds
- salts
- organic
- physiologically tolerable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 16
- 102000017916 BDKRB1 Human genes 0.000 title 1
- 108010044231 Bradykinin B1 Receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 13
- 150000007522 mineralic acids Chemical class 0.000 claims 7
- 150000007524 organic acids Chemical class 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000027109 Headache disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010045171 Tumour pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Claims (10)
1. Spojevi, naznačeni time, da imaju opću formulu I
[image]
u kojoj
R1 je odabran iz skupine koju čine:
[image]
R2 označava H, Cl ili F i X označava CH ili N,
njihovi enantiomeri, njihovi dijastereomeri, njihove smjese i njihove soli, posebno
njihove fiziološki podnošljive soli s organskim ili anorganskim kiselinama ili lužinama.
2. Spojevi prema zahtjevu 1, naznačeni time, da su to spojevi koji imaju opću formulu Ia
[image]
u kojoj
R2 označava H, Cl ili F i X označava CH ili N,
njihovi enantiomeri, njihovi dijastereomeri, njihove smjese i njihove soli, posebno njihove fiziološki podnošljive soli s organskim ili anorganskim kiselinama ili lužinama.
3. Spojevi prema zahtjevu 1, naznačeni time, da su to spojevi koji imaju opću formulu Ib
[image]
u kojoj
R2 označava H, Cl ili F i X označava CH ili N,
njihovi enantiomeri, njihovi dijastereomeri, njihove smjese i njihove soli, posebno njihove fiziološki podnošljive soli s organskim ili anorganskim kiselinama ili lužinama.
4. Spojevi prema zahtjevu 1, naznačeni time, da su to spojevi koji imaju opću formulu Ic
[image]
u kojoj
R2 označava H, Cl ili F i X označava CH ili N,
njihovi enantiomeri, njihovi dijastereomeri, njihove smjese i njihove soli, posebno njihove fiziološki podnošljive soli s organskim ili anorganskim kiselinama ili lužinama.
5. Spojevi prema zahtjevu 1, naznačeni time, da su to spojevi koji imaju opću formulu Id
[image]
u kojoj
R2 označava H, Cl ili F i
X označava CH ili N,
njihovi enantiomeri, njihovi dijastereomeri, njihove smjese i njihove soli, posebno njihove fiziološki podnošljive soli s organskim ili anorganskim kiselinama ili lužinama.
6. Spojevi prema jednom od prethodnih zahtjeva, naznačeni time, da su to spojevi koji imaju sljedeće formule:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
njihovi enantiomeri, njihovi dijastereomeri, njihove smjese i njihove soli, posebno njihove fiziološki podnošljive soli s organskim ili anorganskim kiselinama ili lužinama.
7. Fiziološki podnošljive soli, naznačene time, da su od spojeva prema jednom od prethodnih zahtjeva s anorganskim ili organskim kiselinama ili lužinama.
8. Farmaceutski sastavi, naznačeni time, da obuhvaćaju spojeve prema jednom od prethodnih zahtjeva, opcijski zajedno s jednim ili više inertnih nosača i/ili razrjeđivača.
9. Lijek, naznačen time, da obuhvaća spoj prema jednom od zahtjeva 1 do 7.
10. Spoj prema jednom od zahtjeva 1 do 7, naznačeni time, da se upotrebljava za akutno ili profilaktičko liječenje osteoartritisa, akutnih bolova, organskih bolova, neuropatskih bolova, upalnih bolova/bolova povezanih s receptorom, bolova kod tumora, bolesti s glavoboljom, dijabetske neuropatije, kroničnih bolova u leđima, astme, kroničnog bronhitisa ili COPD-a.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10173489 | 2010-08-20 | ||
| PCT/EP2011/064260 WO2012022795A1 (de) | 2010-08-20 | 2011-08-19 | Disubstituierte tetrahydofuranyl-verbindungen als antagonisten des bradykinin-b1-rezeptors |
| EP11748634.0A EP2606042B1 (de) | 2010-08-20 | 2011-08-19 | Disubstituierte tetrahydofuranyl-verbindungen als antagonisten des bradykinin-b1-rezeptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141172T1 true HRP20141172T1 (hr) | 2015-02-13 |
Family
ID=44510978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141172AT HRP20141172T1 (hr) | 2010-08-20 | 2014-12-02 | Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8937073B2 (hr) |
| EP (1) | EP2606042B1 (hr) |
| JP (1) | JP5727011B2 (hr) |
| KR (1) | KR101822371B1 (hr) |
| CN (1) | CN103068817B (hr) |
| AP (1) | AP2012006630A0 (hr) |
| AR (1) | AR082507A1 (hr) |
| AU (1) | AU2011290727B2 (hr) |
| BR (1) | BR112013003752A2 (hr) |
| CA (1) | CA2807086A1 (hr) |
| CL (1) | CL2013000310A1 (hr) |
| CO (1) | CO6680689A2 (hr) |
| CY (1) | CY1115933T1 (hr) |
| DK (1) | DK2606042T3 (hr) |
| EA (1) | EA022787B1 (hr) |
| EC (1) | ECSP13012495A (hr) |
| ES (1) | ES2525296T3 (hr) |
| GE (1) | GEP20146196B (hr) |
| HK (1) | HK1178902A1 (hr) |
| HR (1) | HRP20141172T1 (hr) |
| IL (1) | IL224039A (hr) |
| MA (1) | MA34578B1 (hr) |
| ME (1) | ME01899B (hr) |
| MX (1) | MX352548B (hr) |
| MY (1) | MY156233A (hr) |
| NZ (1) | NZ607435A (hr) |
| PE (1) | PE20130810A1 (hr) |
| PL (1) | PL2606042T3 (hr) |
| PT (1) | PT2606042E (hr) |
| RS (1) | RS53622B1 (hr) |
| SG (1) | SG187835A1 (hr) |
| SI (1) | SI2606042T1 (hr) |
| TW (1) | TWI548632B (hr) |
| UA (1) | UA108765C2 (hr) |
| UY (1) | UY33565A (hr) |
| WO (1) | WO2012022795A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007034620A1 (de) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| JP5238812B2 (ja) | 2007-08-29 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ブラジキニンｂ１アンタゴニスト |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2016183150A1 (en) * | 2015-05-12 | 2016-11-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2473778A1 (en) | 2002-02-08 | 2003-08-14 | Merck & Co., Inc. | N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| AR038377A1 (es) * | 2002-02-08 | 2005-01-12 | Merck & Co Inc | Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) |
| IL166426A0 (en) | 2002-08-29 | 2006-01-15 | Merck & Co Inc | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| CN1832922A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类 |
| CA2534188A1 (en) * | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| CN1926136A (zh) * | 2004-03-02 | 2007-03-07 | 默克公司 | 作为缓激肽拮抗剂的氨基环丙烷羧酰胺衍生物 |
| US20060173023A1 (en) | 2005-02-01 | 2006-08-03 | Wood Michael R | 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation |
| US7998980B2 (en) * | 2006-09-15 | 2011-08-16 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| EP2025675A1 (de) | 2007-08-14 | 2009-02-18 | Boehringer Ingelheim International GmbH | Arylsulfonamide mit analgetischer Wirkung |
| JP5238812B2 (ja) * | 2007-08-29 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ブラジキニンｂ１アンタゴニスト |
| AR068509A1 (es) * | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| WO2010057899A1 (de) | 2008-11-20 | 2010-05-27 | Boehringer Ingelheim International Gmbh | Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten |
| PE20120360A1 (es) | 2009-02-26 | 2012-04-14 | Boehringer Ingelheim Int | Compuestos en calidad de antagonistas de bradiquinina b1 |
| WO2010097374A1 (de) | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
| EP2539323B3 (de) | 2010-02-23 | 2017-10-04 | Boehringer Ingelheim International GmbH | Verbindungen als Bradykinin-B1-Antagonisten |
| PL2606044T3 (pl) | 2010-08-20 | 2014-09-30 | Allergan Inc | Związki, które działają na wiele receptorów prostaglandyn, wywołujące ogólną odpowiedź przeciwzapalną |
| JP5727010B2 (ja) * | 2010-08-20 | 2015-06-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブラジキニンｂ１受容体のアンタゴニストとしてのピリダジン誘導体 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
-
2011
- 2011-08-12 US US13/208,567 patent/US8937073B2/en active Active
- 2011-08-19 PE PE2013000265A patent/PE20130810A1/es not_active Application Discontinuation
- 2011-08-19 AP AP2012006630A patent/AP2012006630A0/xx unknown
- 2011-08-19 UA UAA201303313A patent/UA108765C2/uk unknown
- 2011-08-19 PL PL11748634T patent/PL2606042T3/pl unknown
- 2011-08-19 AR ARP110103036A patent/AR082507A1/es not_active Application Discontinuation
- 2011-08-19 MY MYPI2013000537A patent/MY156233A/en unknown
- 2011-08-19 TW TW100129857A patent/TWI548632B/zh active
- 2011-08-19 JP JP2013524457A patent/JP5727011B2/ja active Active
- 2011-08-19 WO PCT/EP2011/064260 patent/WO2012022795A1/de active Application Filing
- 2011-08-19 SI SI201130320T patent/SI2606042T1/sl unknown
- 2011-08-19 MX MX2013001965A patent/MX352548B/es active IP Right Grant
- 2011-08-19 NZ NZ607435A patent/NZ607435A/en not_active IP Right Cessation
- 2011-08-19 UY UY0001033565A patent/UY33565A/es not_active Application Discontinuation
- 2011-08-19 AU AU2011290727A patent/AU2011290727B2/en not_active Ceased
- 2011-08-19 PT PT117486340T patent/PT2606042E/pt unknown
- 2011-08-19 KR KR1020137004077A patent/KR101822371B1/ko active IP Right Grant
- 2011-08-19 BR BR112013003752A patent/BR112013003752A2/pt not_active IP Right Cessation
- 2011-08-19 RS RS20140551A patent/RS53622B1/en unknown
- 2011-08-19 ES ES11748634.0T patent/ES2525296T3/es active Active
- 2011-08-19 SG SG2013010764A patent/SG187835A1/en unknown
- 2011-08-19 EP EP11748634.0A patent/EP2606042B1/de active Active
- 2011-08-19 DK DK11748634.0T patent/DK2606042T3/da active
- 2011-08-19 CN CN201180039753.8A patent/CN103068817B/zh not_active Expired - Fee Related
- 2011-08-19 CA CA2807086A patent/CA2807086A1/en not_active Abandoned
- 2011-08-19 GE GEAP201113031A patent/GEP20146196B/en unknown
- 2011-08-19 EA EA201201662A patent/EA022787B1/ru not_active IP Right Cessation
- 2011-08-19 ME MEP-2014-118A patent/ME01899B/me unknown
- 2011-08-19 MA MA35624A patent/MA34578B1/fr unknown
-
2012
- 2012-12-31 IL IL224039A patent/IL224039A/en active IP Right Grant
-
2013
- 2013-01-30 CL CL2013000310A patent/CL2013000310A1/es unknown
- 2013-02-28 CO CO13041062A patent/CO6680689A2/es active IP Right Grant
- 2013-03-15 EC ECSP13012495 patent/ECSP13012495A/es unknown
- 2013-06-04 HK HK13106521.0A patent/HK1178902A1/xx not_active IP Right Cessation
-
2014
- 2014-11-26 CY CY20141100985T patent/CY1115933T1/el unknown
- 2014-12-02 HR HRP20141172AT patent/HRP20141172T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141172T1 (hr) | Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| RS54020B1 (en) | ORGANOBOR ESTAR UNITS AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| EA201101026A1 (ru) | Ингибиторы бета-секретазы | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
| EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
| EA201690520A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
| EA201290726A1 (ru) | Новые соли для получения фармацевтических композиций | |
| BR112012019672A2 (pt) | pirrolidina-2-carboxamidas substituídas. | |
| BR112014007134A2 (pt) | usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| EA201490152A1 (ru) | Антагонисты trpm8 и их применение при лечении | |
| EA201201167A1 (ru) | Соединения в качестве антагонистов брадикинина b1 | |
| EA201792597A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
| BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
| WO2016025933A3 (en) | Substituted polycyclic antibacterial compounds | |
| EA201891804A1 (ru) | Тетрациклиновые соединения | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
| EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
| EA201270302A1 (ru) | Безводные формы производных пиридина | |
| RS53772B1 (en) | ALISKIREN SYNTHESIS | |
| SG195136A1 (en) | Trpv1 antagonists including dihydroxy substituent and uses thereof |